Publikationen, an denen er mitarbeitet Juan Suárez Pérez (24)

2023

  1. Antidepressant Medication Does Not Contribute to the Elevated Circulating Concentrations of Acylethanolamides Found in Substance Use Disorder Patients

    International Journal of Molecular Sciences, Vol. 24, Núm. 19

  2. Antipsychotic Medication Influences the Discriminative Value of Acylethanolamides as Biomarkers of Substance Use Disorder

    International journal of molecular sciences, Vol. 24, Núm. 11

  3. Plasma Concentrations of Neurofilament Light Chain Protein and Brain-Derived Neurotrophic Factor as Consistent Biomarkers of Cognitive Impairment in Alcohol Use Disorder

    International Journal of Molecular Sciences, Vol. 24, Núm. 2

2022

  1. Discovery of V-0219: A Small-Molecule Positive Allosteric Modulator of the Glucagon-Like Peptide-1 Receptor toward Oral Treatment for "diabesity"

    Journal of Medicinal Chemistry, Vol. 65, Núm. 7, pp. 5449-5461

  2. Sex Differences in Plasma Lysophosphatidic Acid Species in Patients with Alcohol and Cocaine Use Disorders

    Brain Sciences, Vol. 12, Núm. 5

  3. Vascular Endothelial Growth Factor as a Potential Biomarker of Neuroinflammation and Frontal Cognitive Impairment in Patients with Alcohol Use Disorder

    Biomedicines, Vol. 10, Núm. 5

2021

  1. Abrupt cessation of reboxetine along alcohol deprivation results in alcohol intake escalation after reinstatement of drinking

    Addiction Biology, Vol. 26, Núm. 3

  2. Evaluation of neurotrophic factors and education level as predictors of cognitive decline in alcohol use disorder

    Scientific Reports, Vol. 11, Núm. 1

  3. Influence of gender and education on cocaine users in an outpatient cohort in Spain

    Scientific Reports, Vol. 11, Núm. 1

  4. Plasma concentrations of lysophosphatidic acid and autotaxin in abstinent patients with alcohol use disorder and comorbid liver disease

    Biomedicines, Vol. 9, Núm. 9

  5. Sex-specific behavioral and neurogenic responses to cocaine in mice lacking and blocking dopamine D1 or dopamine D2 receptors

    Journal of Comparative Neurology, Vol. 529, Núm. 8, pp. 1724-1742

  6. Sudden cessation of fluoxetine before alcohol drinking reinstatement alters microglial morphology and TLR4/inflammatory neuroadaptation in the rat brain

    Brain Structure and Function, Vol. 226, Núm. 7, pp. 2243-2264

2020

  1. Abstinent patients with alcohol use disorders show an altered plasma cytokine profile: Identification of both interleukin 6 and interleukin 17A as potential biomarkers of consumption and comorbid liver and pancreatic diseases

    Journal of Psychopharmacology, Vol. 34, Núm. 11, pp. 1250-1260

  2. Cessation of fluoxetine treatment increases alcohol seeking during relapse and dysregulates endocannabinoid and glutamatergic signaling in the central amygdala

    Addiction Biology, Vol. 25, Núm. 5

  3. Cocaine-induced changes in CX3CL1 and inflammatory signaling pathways in the hippocampus: Association with IL1β

    Neuropharmacology, Vol. 162

  4. Plasma tryptophan and kynurenine pathway metabolites in abstinent patients with alcohol use disorder and high prevalence of psychiatric comorbidity

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 102

  5. Potential association of plasma lysophosphatidic acid (LPA) species with cognitive impairment in abstinent alcohol use disorders outpatients

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Alcohol-induced cognitive deficits are associated with decreased circulating levels of the neurotrophin BDNF in humans and rats

    Addiction Biology, Vol. 24, Núm. 5, pp. 1019-1033

  2. Oleoylethanolamide modulates BDNF-ERK signaling and neurogenesis in the hippocampi of rats exposed to δ9-THC and ethanol binge drinking during adolescence

    Frontiers in Molecular Neuroscience, Vol. 12

  3. Perinatal free-choice of a high-calorie low-protein diet affects leptin signaling through IRS1 and AMPK dephosphorylation in the hypothalami of female rat offspring in adulthood

    Acta Physiologica, Vol. 226, Núm. 2